Literature DB >> 11350606

Enhanced expression of basement-membrane-type heparan sulfate proteoglycan in tumor fibro-myxoid stroma of intrahepatic cholangiocarcinoma.

H Sabit1, K Tsuneyama, T Shimonishi, K Harada, J Cheng, H Ida, T Saku, K Saito, Y Nakanuma.   

Abstract

To investigate the molecular mechanism for enhanced fibrous stroma formation in intrahepatic cholangiocarcinoma (ICC), we surveyed the expression pattern of basement-membrane-type heparan sulfate proteoglycan (HSPG; also known as perlecan) at the core protein and the mRNA level in ICC as well as in other liver neoplasms and reactive hepatic diseases. Immunohistochemistry of paraffin-embedded liver sections with hyaluronidase pretreatment showed that HSPG was present in small amounts in normal liver around the bile ducts and the blood vessels within the portal area. There was no evident expression within the hepatic lobules. Intense immunoexpression of HSPG was seen in the tumor-specific fibro-myxoid stroma of ICC and metastatic liver cancer originating from the colon. However, tumor-specific stroma of hepatocellular carcinomas showed little or no expression of HSPG. At the mRNA level, signals for HSPG were found in tumor cells of cholangiocarcinoma and metastatic colonic carcinomas, and in myofibroblasts in the tumor fibro-myxoid-specific stroma. From immunoprecipitation and reverse transcription-polymerase chain reaction (RT-PCR) analyses, a cultured human intrahepatic cholangiocarcinoma cell line (CCKS1), was found to express high levels of HSPG core protein and mRNA. These findings suggest that biliary and metastatic colon carcinoma cells as well as stromal myofibroblasts have a potential for HSPG production. In order to investigate the growth, invasion and metastatic ability of ICC, further study of the 'self-made' stromal component of ICC may provide a new approach.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350606     DOI: 10.1046/j.1440-1827.2001.01201.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

Review 1.  Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.

Authors:  Atit Silsirivanit; Kanlayanee Sawanyawisuth; Gregory J Riggins; Chaisiri Wongkham
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

2.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

Authors:  Shusaku Ohira; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Yoh Zen; Kumiko Isse; Kazuto Kozaka; Akira Ishikawa; Koji Oda; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

3.  Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment.

Authors:  Kar Wai Tan; Maximilien Evrard; Muly Tham; Michelle Hong; Caleb Huang; Masashi Kato; Armelle Prevost-Blondel; Emmanuel Donnadieu; Lai Guan Ng; Jean-Pierre Abastado
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

4.  Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling.

Authors:  Malin Jansson; Ola Billing; Carl Herdenberg; Christina Lundin; Egle Tolockiene; Anoosheh Nazemroaya; Malin Sund
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-02       Impact factor: 2.673

5.  3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.

Authors:  Onanong Buhome; Molin Wongwattanakul; Jureerut Daduang; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 6.  Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist?

Authors:  Stefan M Willems; Malgorzata Wiweger; J Frans Graadt van Roggen; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-08-25       Impact factor: 4.064

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment.

Authors:  Curtis R Warren; Brian J Grindel; Lewis Francis; Daniel D Carson; Mary C Farach-Carson
Journal:  J Cell Biochem       Date:  2014-07       Impact factor: 4.429

9.  SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer.

Authors:  Shanshan Wang; Haibo Han; Ying Hu; Wei Yang; Yunwei Lv; Limin Wang; Lianhai Zhang; Jiafu Ji
Journal:  Oncotarget       Date:  2017-07-25

Review 10.  Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan.

Authors:  Zehra Elgundi; Michael Papanicolaou; Gretel Major; Thomas R Cox; James Melrose; John M Whitelock; Brooke L Farrugia
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.